Choosing a better end point for trials of bone-protective agents

Choosing a better end point for trials of bone-protective agents.

authors argue that calibration is a more important statistic than discrimination because a patient wants a model that predicts his risk accurately rather than one that distinguishes between men at higher and lower risk. Both aspects are important and models should be evaluated based on both discrimination and calibration. We agree that calibration should be more widely reported, but disagree th...

Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point

Idiopathic pulmonary fibrosis (IPF), the most common and lethal of all idiopathic interstitial pneumonias, is a disease that is both rare and orphan. However, in the last decade more than 3000 patients have been enrolled in high-quality clinical trials of IPF, an impressive achievement for a rare condition. The most challenging obstacle in clinical trials of orphan drugs is the recruitment of a...

Repeat revascularization is a faulty end point for clinical trials.

Coronary revascularization is performed to reduce myocardial ischemia and its sequelae of death, myocardial infarction, and anginal symptoms. A successful procedure increases the patient’s quality of life, length of life, or both. Clinical trials of coronary revascularization should measure these outcomes to assess progress toward the goals of therapy. Death is an important and unequivocal outc...

00046 A Better Choosing Experience

Choosing Better Challenge Questions

Challenge questions are an increasingly important part of mainstream authentication solutions, yet there are few published studies concerning their usability or security. This paper reports on an experimental investigation into userchosen questions. We collected questions from a large cohort of students, in a way that encouraged participants to give realistic data. The questions allow us to con...